Matches in SemOpenAlex for { <https://semopenalex.org/work/W155120211> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W155120211 endingPage "36" @default.
- W155120211 startingPage "28" @default.
- W155120211 abstract "Classical (typical) antipsychotic drugs are in wide use clinically, but some patients do not respond at all to treatment, while in others, negative symptoms and cognitive deficits fail to respond. Also, these drugs often cause serious motor disturbances. Clozapine, an atypical antipsychotic, appears to correct many of these deficiencies, but has a significant incidence of potentially fatal agranulocytosis. Accordingly, we attempted to develop a prototype of a new generation of antipsychotics that is both more efficacious and safe. Our strategy was to create a compound that is not only active in behavioral tests that predict antipsychotic action but also shares the rich, multifaceted receptor pharmacology of clozapine without its side effects. To this end, Eli Lilly and Co. developed olanzapine. In this article we characterize the in vitro and in vivo receptor pharmacology of olanzapine.We evaluated olanzapine interactions with neuronal receptors using standard assays of radioreceptor binding in vitro and well-established in vivo (functional) assays.Binding studies showed that olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscarinic receptors. In vivo olanzapine is a potent antagonist at DA receptors (DOPAC levels; pergolide-stimulated increases in plasma corticosterone) and 5-HT receptors (quipazine-stimulated increases in corticosterone), but is weaker at alpha-adrenergic and muscarinic receptors. Olanzapine has little or no effect at other receptors, enzymes, or key proteins in neuronal function. Olanzapine has a receptor profile that is similar to that of clozapine: it is relatively nonselective at dopamine receptor subtypes and it shows selectivity for mesolimbic and mesocortical over striatal dopamine tracts (electrophysiology; Fos).The binding and functional profile of olanzapine (1) is similar to that of clozapine, (2) indicates that olanzapine is an atypical antipsychotic drug, and (3) is consistent with clinical efficacy. If olanzapine also proves to be safe, then it will have high potential to become a more ideal antipsychotic drug." @default.
- W155120211 created "2016-06-24" @default.
- W155120211 creator A5041481102 @default.
- W155120211 creator A5062965562 @default.
- W155120211 date "1997-01-01" @default.
- W155120211 modified "2023-09-23" @default.
- W155120211 title "In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug." @default.
- W155120211 cites W1970814820 @default.
- W155120211 cites W1977275629 @default.
- W155120211 cites W1977381163 @default.
- W155120211 cites W2026275409 @default.
- W155120211 cites W2042333804 @default.
- W155120211 cites W2087614780 @default.
- W155120211 cites W2109865728 @default.
- W155120211 cites W2887788245 @default.
- W155120211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9265914" @default.
- W155120211 hasPublicationYear "1997" @default.
- W155120211 type Work @default.
- W155120211 sameAs 155120211 @default.
- W155120211 citedByCount "60" @default.
- W155120211 countsByYear W1551202112012 @default.
- W155120211 countsByYear W1551202112013 @default.
- W155120211 countsByYear W1551202112015 @default.
- W155120211 countsByYear W1551202112016 @default.
- W155120211 countsByYear W1551202112017 @default.
- W155120211 countsByYear W1551202112018 @default.
- W155120211 countsByYear W1551202112019 @default.
- W155120211 countsByYear W1551202112021 @default.
- W155120211 countsByYear W1551202112022 @default.
- W155120211 crossrefType "journal-article" @default.
- W155120211 hasAuthorship W155120211A5041481102 @default.
- W155120211 hasAuthorship W155120211A5062965562 @default.
- W155120211 hasConcept C118552586 @default.
- W155120211 hasConcept C126322002 @default.
- W155120211 hasConcept C134018914 @default.
- W155120211 hasConcept C170493617 @default.
- W155120211 hasConcept C2775870346 @default.
- W155120211 hasConcept C2776412080 @default.
- W155120211 hasConcept C2776619155 @default.
- W155120211 hasConcept C2776921671 @default.
- W155120211 hasConcept C2780494398 @default.
- W155120211 hasConcept C2780864610 @default.
- W155120211 hasConcept C71924100 @default.
- W155120211 hasConcept C98274493 @default.
- W155120211 hasConceptScore W155120211C118552586 @default.
- W155120211 hasConceptScore W155120211C126322002 @default.
- W155120211 hasConceptScore W155120211C134018914 @default.
- W155120211 hasConceptScore W155120211C170493617 @default.
- W155120211 hasConceptScore W155120211C2775870346 @default.
- W155120211 hasConceptScore W155120211C2776412080 @default.
- W155120211 hasConceptScore W155120211C2776619155 @default.
- W155120211 hasConceptScore W155120211C2776921671 @default.
- W155120211 hasConceptScore W155120211C2780494398 @default.
- W155120211 hasConceptScore W155120211C2780864610 @default.
- W155120211 hasConceptScore W155120211C71924100 @default.
- W155120211 hasConceptScore W155120211C98274493 @default.
- W155120211 hasLocation W1551202111 @default.
- W155120211 hasOpenAccess W155120211 @default.
- W155120211 hasPrimaryLocation W1551202111 @default.
- W155120211 hasRelatedWork W1875432782 @default.
- W155120211 hasRelatedWork W1973464250 @default.
- W155120211 hasRelatedWork W1990396073 @default.
- W155120211 hasRelatedWork W1992156446 @default.
- W155120211 hasRelatedWork W2009770372 @default.
- W155120211 hasRelatedWork W2053754882 @default.
- W155120211 hasRelatedWork W2130760967 @default.
- W155120211 hasRelatedWork W2136998913 @default.
- W155120211 hasRelatedWork W2964860399 @default.
- W155120211 hasRelatedWork W2409890879 @default.
- W155120211 hasVolume "58 Suppl 10" @default.
- W155120211 isParatext "false" @default.
- W155120211 isRetracted "false" @default.
- W155120211 magId "155120211" @default.
- W155120211 workType "article" @default.